Abstract
Pancreatic carcinoma is the fifth leading cause of cancer-related mortality. The 5-year overall survival is less than 5 %. This very poor prognosis can be explained both by late diagnosis and by treatment resistance, including resistance to radiation therapy. A better understanding of the pancreatic tumorigenesis and knowledge of the most frequent mutations in pancreatic adenocarcinoma (KRAS, p16, TP53, Smad4) open new perspectives for the development of more effective treatments. This review presents the major genetic and molecular alterations in pancreatic cancer that could be targeted to improve radiosensitization.
Copyright © 2011 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.
Publication types
-
English Abstract
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antimetabolites, Antineoplastic / pharmacokinetics
-
Antimetabolites, Antineoplastic / therapeutic use
-
Carcinoma in Situ / genetics
-
Carcinoma in Situ / pathology
-
Carcinoma, Pancreatic Ductal / diagnosis
-
Carcinoma, Pancreatic Ductal / drug therapy
-
Carcinoma, Pancreatic Ductal / epidemiology
-
Carcinoma, Pancreatic Ductal / genetics*
-
Carcinoma, Pancreatic Ductal / pathology
-
Carcinoma, Pancreatic Ductal / radiotherapy
-
Cell Transformation, Neoplastic / genetics*
-
Cystadenoma, Mucinous / pathology
-
Delayed Diagnosis
-
Deoxycytidine / analogs & derivatives
-
Deoxycytidine / pharmacokinetics
-
Deoxycytidine / therapeutic use
-
Disease Progression
-
Gemcitabine
-
Genes, Tumor Suppressor
-
Humans
-
Intercellular Signaling Peptides and Proteins / physiology
-
Mutation
-
Neoplasm Proteins / antagonists & inhibitors
-
Neoplasm Proteins / physiology
-
Oncogenes
-
Pancreatic Neoplasms / diagnosis
-
Pancreatic Neoplasms / drug therapy
-
Pancreatic Neoplasms / epidemiology
-
Pancreatic Neoplasms / genetics*
-
Pancreatic Neoplasms / pathology
-
Pancreatic Neoplasms / radiotherapy
-
Precancerous Conditions / pathology
-
Radiation Tolerance
-
Signal Transduction / genetics
Substances
-
Antimetabolites, Antineoplastic
-
Intercellular Signaling Peptides and Proteins
-
Neoplasm Proteins
-
Deoxycytidine
-
Gemcitabine